Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

No reported EBITDA figures are available to summarize.

EBITDA history

Currency unavailable · from the income statement

No EBITDA data reported for this period type.

EBITDA vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
EBITDA for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IKTInhibikase Therapeutics, Inc.LTM Mar 2026-$53.92M USD-39.7%——
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$75.47M USD+22.0%—33540.9%
RNAAtrium Therapeutics, Inc.FY2025-$76.5M USD——410.9%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-$254.91M USD-32.5%—3579.7%
CYTKCytokinetics, IncorporatedLTM Jun 2026-$821.8M USD-62.8%—1158.1%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —-36.1%—2368.9%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.